

Mr Christopher Feinmann  
Project Manager  
National Institute for Clinical Excellence (NICE)  
Peter House  
Oxford Street  
MANCHESTER M1 5AN

Your ref:

Our Ref: [REDACTED]

15 January 2008

Dear Mr Feinmann

**RE: HTA Appraisal; Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma.**

Thank you for inviting Kidney Research UK to participate in this consultation. We have now reviewed the protocol (26 October 2007) for the above appraisal with both our medical advisors (with specific expertise) and our patient advisors. All are happy with the proposed approach and consider it appropriate for the task.

We would, however, like to feedback a few comments which may not be derived from published literature that the NICE Appraisal Committee may wish to consider at their meeting;

- a) No potential treatment has been missed.
- b) Potential consideration of a combination of these drugs (although we accept this may be due to there being no clinical trials yet), or
- c) The scenario of failure with one drug leading to the introduction of another.
- d) There is evidence of secondary response when a drug is introduced following failure on one of the others despite their similarity of mode of action – this aspect may be beneficial to include.

Our patient advisors have no further evidence that would be beneficial to the committee in their appraisal process.

If you have any further questions please do not hesitate to contact me.

Yours sincerely,

[REDACTED]